A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772

This study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the combination of T-DXd with bevacizumab.Part 2 (randomized part) will start only after the safety run-in is completed and the combination of combination of T-DXd with bevacizumab is considered safe. The purpose of this main part is to learn if the combination of both study drugs work better than bevacizumab alone.